<div id="readability-page-1"><p>QuidelOrtho Corporation (NASDAQ:QDEL - Get Free Report) Director Joseph Jr. Wilkins bought 370 shares of the business's stock in a transaction on Wednesday, November 26th. The stock was acquired at an average cost of $27.95 per share, for a total transaction of $10,341.50. Following the acquisition, the director directly owned 11,876 shares of the company's stock, valued at $331,934.20. The trade was a 3.22% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.</p><h2>QuidelOrtho Stock Performance</h2><ul><li>Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11</li></ul><p>Shares of NASDAQ:QDEL traded down $0.87 during trading on Monday, hitting $26.48. 746,960 shares of the company traded hands, compared to its average volume of 1,346,261. The company has a quick ratio of 0.62, a current ratio of 1.12 and a debt-to-equity ratio of 0.74. The business's fifty day moving average is $26.62 and its 200-day moving average is $27.70. The stock has a market capitalization of $1.80 billion, a price-to-earnings ratio of -4.05 and a beta of 0.35. QuidelOrtho Corporation has a one year low of $19.50 and a one year high of $49.45. </p><p>QuidelOrtho (NASDAQ:QDEL - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.51 by $0.29. The business had revenue of $699.90 million during the quarter, compared to analyst estimates of $667.45 million. QuidelOrtho had a positive return on equity of 5.29% and a negative net margin of 16.10%.The business's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.85 EPS.  QuidelOrtho has set its FY 2025 guidance at 2.000-2.150 EPS. As a group, equities analysts predict that  QuidelOrtho Corporation will post 2.3 earnings per share for the current fiscal year. </p><h2>Institutional Trading of QuidelOrtho</h2><p>Hedge funds and other institutional investors have recently modified their holdings of the business. Clear Harbor Asset Management LLC grew its stake in  QuidelOrtho by 147.5% during the 2nd quarter. Clear Harbor Asset Management LLC now owns 34,186 shares of the company's stock valued at $985,000 after acquiring an additional 20,374 shares in the last quarter.  Nordea Investment Management AB acquired a new stake in shares of  QuidelOrtho during the second quarter worth approximately $2,609,000.  Dynamic Technology Lab Private Ltd purchased a new position in  QuidelOrtho during the first quarter valued at approximately $411,000.  Lightrock Netherlands B.V. grew its position in  QuidelOrtho by 27.8% during the second quarter. Lightrock Netherlands B.V. now owns 466,000 shares of the company's stock valued at $13,430,000 after purchasing an additional 101,423 shares in the last quarter.  Finally, Brighton Jones LLC acquired a new position in  QuidelOrtho in the 2nd quarter valued at approximately $384,000. Institutional investors and hedge funds own  99.00% of the company's stock. </p><h2>Analyst Ratings Changes</h2><p>Several equities analysts have recently commented on the stock. UBS Group upped their price target on shares of QuidelOrtho from $26.00 to $31.00 and gave the stock a &#34;neutral&#34; rating in a research report on Thursday, November 6th. Zacks Research lowered shares of QuidelOrtho from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note on Monday, October 13th. Citigroup  reaffirmed a &#34;neutral&#34; rating and set a $33.00 price target (down previously from $40.00) on shares of QuidelOrtho in a report on Tuesday, October 7th. JPMorgan Chase &amp; Co. reduced their price objective on QuidelOrtho from $26.00 to $22.00 and set an &#34;underweight&#34; rating for the company in a research report on Friday, November 7th. Finally, Weiss Ratings  restated a &#34;sell (e+)&#34; rating on shares of QuidelOrtho in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and three have issued  a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Reduce&#34; and a consensus target price of $38.20.</p><p><b>Read Our Latest Analysis on QuidelOrtho</b></p><h2>About QuidelOrtho</h2> (Get Free Report)<p>QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than QuidelOrtho</li><li>Dividend King Proctor &amp; Gamble Is A Buy On Post-Earnings Weakness </li><li>Congress Beat the Market Again—Here Are the 3 Stocks They Bought</li><li>Investing In Automotive Stocks</li><li>Go on a Shopping Spree With 3 Top Retail ETFs</li><li>Buy P&amp;G Now, Before It Sets A New All-Time High</li><li>If D-Wave Is Too Risky, Consider These 3 Quantum ETFs for Diversification</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in QuidelOrtho Right Now?</h2><p>Before you consider QuidelOrtho, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and QuidelOrtho wasn't on the list.</p><p>While QuidelOrtho currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

QDEL

<p>QuidelOrtho Director Joseph Jr. Wilkins purchased 370 shares at $27.95 each, totaling $10,341.50, increasing his ownership by 3.22%. The stock traded at $26.48, with a market cap of $1.80 billion. QuidelOrtho reported $0.80 EPS, beating estimates, but revenue fell 3.7% year-over-year. Analysts have mixed ratings, with a consensus target price of $38.20. Institutional investors hold 99% of the stock.</p>

Insider Buying: QuidelOrtho (NASDAQ:QDEL) Director Purchases 370 Shares of Stock